George W Sledge Jr
Overview
Explore the profile of George W Sledge Jr including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
148
Citations
5039
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bansal R, Adeyelu T, Elliott A, Tan A, Ribeiro J, Meisel J, et al.
JCO Precis Oncol
. 2024 Dec;
8:e2400289.
PMID: 39637336
Purpose: Malignant phyllodes tumors (MPTs) are rare fibroepithelial tumors of the breast with aggressive biologic behavior and high recurrence rates. Surgery remains the primary treatment modality for these tumors; however,...
2.
Stearns V, ONeill A, Schneider B, Skaar T, Liu M, Lohrisch C, et al.
Breast Cancer Res Treat
. 2024 Oct;
209(3):595-602.
PMID: 39432161
Purpose: In tamoxifen-treated individuals, reduced-function genetic variants in the CYP2D6 gene or inhibition of the enzyme result in low circulating endoxifen concentrations. We assessed the impact of reduced CYP2D6 activity...
3.
Chowdhury S, Xiu J, Ribeiro J, Nicolaides T, Zhang J, Korn W, et al.
Br J Cancer
. 2024 Sep;
131(8):1328-1339.
PMID: 39227409
Background: We developed a whole transcriptome sequencing (WTS)-based Consensus Molecular Subtypes (CMS) classifier using FFPE tissue and investigated its prognostic and predictive utility in a large clinico-genomic database of CRC...
4.
Sammons S, Elliott A, Barroso-Sousa R, Chumsri S, Tan A, Sledge Jr G, et al.
Front Oncol
. 2023 Aug;
13:1235902.
PMID: 37637072
Background: Data supporting high tumor mutational burden (TMB-H) as a lone biomarker for an immune-responsive tumor microenvironment (TME) in metastatic breast cancer (MBC) are weak, yet tumor agnostic approval in...
5.
Toi M, Huang C, Im Y, Sohn J, Zhang W, Sakaguchi S, et al.
Cancer Sci
. 2022 Sep;
114(1):221-226.
PMID: 36168844
MONARCH 2 is a global, randomized, double-blind, phase 3 study of abemaciclib/placebo + fulvestrant in patients with hormone receptor positive, human epidermal growth factor receptor 2-negative advanced breast cancer. The...
6.
Parikh D, Kody L, Brain S, Heditsian D, Lee V, Curtis C, et al.
Breast Cancer Res Treat
. 2022 May;
194(1):171-178.
PMID: 35538268
Purpose: Window of opportunity trials (WOT) are increasingly common in oncology research. In WOT participants receive a drug between diagnosis and anti-cancer treatment, usually for the purpose of investigating that...
7.
Ballinger T, Jiang G, Shen F, Miller K, Sledge Jr G, Schneider B
Cancer
. 2022 Mar;
128(11):2174-2181.
PMID: 35285940
Background: African ancestry (AA) and obesity are associated with worse survival in early-stage breast cancer. Obesity disproportionately affects women of AA; however, the intersection between ancestry and obesity on breast...
8.
Neven P, Rugo H, Tolaney S, Iwata H, Toi M, Goetz M, et al.
Breast Cancer Res
. 2021 Aug;
23(1):87.
PMID: 34425869
Background: In MONARCH 2, abemaciclib plus fulvestrant significantly improved median progression-free survival (PFS, 16.4 vs 9.3 months, hazard ratio [HR] 0.553) and overall survival (OS, 46.7 vs 37.3 months; HR...
9.
Gordon M, Nemunaitis J, Barve M, Wainberg Z, Hamilton E, Ramanathan R, et al.
Mol Cancer Ther
. 2021 Jul;
20(10):1988-1995.
PMID: 34315767
Dilpacimab (formerly ABT-165), a novel dual-variable domain immunoglobulin, targets both delta-like ligand 4 (DLL4) and VEGF pathways. Here, we present safety, pharmacokinetic (PK), pharmacodynamic (PD), and preliminary efficacy data from...
10.